AstraZeneca PLC (AZN)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)
AZN
AstraZeneca PLC
$166.27
-1.05%
HEALTHCARE · Cap: $263.12B
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$11.73
-1.92%
HEALTHCARE · Cap: $1.19B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5781% more annual revenue ($61.37B vs $1.04B). AZN leads profitability with a 17.0% profit margin vs -2.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
LMRI
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.3%
Fair Value
$196.36
Current Price
$166.27
$30.09 discount
Intrinsic value data unavailable for LMRI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 3.2%
ROE of -10.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.44 suggests the stock is reasonably priced for its growth.
Bull Case : LMRI
The strongest argument for LMRI centers on Debt/Equity, Price/Book.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LMRI
The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while LMRI is a turnaround play — different risk/reward profiles.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 35/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Lumexa Imaging Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?